Open
Actively Recruiting
Basimglurant in Children and Adolescents With TSC
About
Brief Summary
The study intends to show that basimglurant provides effective seizure control in children and adolescents with Tuberous Sclerosis Complex (TSC).
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria (summary):
- Ability and willingness to provide informed assent or written consent or consent from their legal representative.
- Fluency in the language of the study staff
- Age 5 to 18 years
- A documented history of TSC,
- Refractory seizure treatment status
- Currently receiving one or more anti-epileptic drugs (AEDs)
- Stable medications or interventions for epilepsy
- Willingness to complete Patient Reported Outcome
- For female patients of childbearing potential:
- Willingness to undergo serum or urinary pregnancy testing at screening and during the trial period.
- Willingness to use contraception.
Exclusion Criteria (summary):
- Neurologic disease other than TSC.
- Recent anoxic episode
- Patient weight below 15kg
- Clinically significant unstable medical condition(s).
- Pregnancy or lactation.
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
21-001187
Category
Neurology
Pediatrics
Urology
Principal Investigator
Contact
Location
- UCLA Westwood